Filing Details
- Accession Number:
- 0001610717-23-000259
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-06 20:02:45
- Reporting Period:
- 2023-09-01
- Accepted Time:
- 2023-09-06 20:02:45
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1628171 | Revolution Medicines Inc. | RVMD | Biological Products, (No Disgnostic Substances) (2836) | 472029180 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1800668 | Jack Anders | C/O Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-09-01 | 20,000 | $2.68 | 75,094 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-09-01 | 20,000 | $35.05 | 55,094 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2023-09-01 | 20,000 | $0.00 | 20,000 | $2.68 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 42,201 | 2022-08-16 | 2028-09-26 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person adopted on March 27, 2023.
- Includes 44,276 restricted stock units.
- This transaction was executed in multiple trades in prices ranging from $35.00 to $35.24, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Billionaire Hedge Funds
